Featured

Tumoral RNA splicing: source of neoantigens for off-the-shelf therapies?

Immunotherapies targeting tumor-specific antigens (TSAs) derived from somatic mutations have limited potential in tumors with low mutational burdens. A recently discovered source of TSAs are cancer-specific splicing events (neojunctions; NJs)...

Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33

Lamorte et al. investigated the role of medullary sinus macrophages (MSMs) in tumor-draining lymph nodes (TDLNs) in regulating mechanisms of cancer therapy resistance. Phagocytosis of murine apoptotic...

Regulatory T cells constrain T cells of shared specificity to enforce tolerance during infection

Adoptive transfer of transgenic Tconv cells against the prostate self-peptide C4 did not induce autoimmunity and prompted polyclonal Treg accumulation around Tconv. Infection with a C4-expressing viru...

Clonal driver neoantigen loss under EGFR TKI and immune selection pressures

Bakir and Reading et al. reported the loss of an EGFR ex19del driver mutation in a patient treated with osimertinib and a personalized neopeptide vaccine (NPV) targeting ten somatic mutations, includi...

Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer

Raja and Mangalaparthi et al. demonstrated that non-coding cryptic peptides are an important class of immunogenic antigens in ovarian cancer (OC). Proteogenomic analysis identified cryptic HLA class I...

See all for this week

Previous Digests

AACR IO 2025

March 5, 2025

The ACIR team attended the newly established AACR IO meeting held on February 23-26, 2025 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below...

TLR agonism and PD-1 blockade unfortunately activate suppressor cells

February 26, 2025

The activation of an immune response involves a system of checks and balances. While immunotherapies can be used to tip the scales, they are not always effective, as resistance mechanisms may act to counter desired responses. In research recently...

Neoantigen vaccination shows promising prevention of recurrence of high-risk kidney cancer

February 19, 2025

Kidney cancer is a common cancer type, and about 75-80% of cases are clear cell renal cell carcinoma (RCC). Patients with RCC are often faced with a high risk of cancer recurrence after complete surgical removal. In a recent...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

— Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Testimonials